UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Conservation of Amino Acids in Human Rhinovirus 3C Protease Correlates with Broad-Spectrum Antiviral Activity of Rupintrivir, a Novel Human Rhinovirus 3C Protease Inhibitor

Antimicrobial Agents and Chemotherapy, 2005-02, Vol.49 (2), p.619-626

2005

Volltextzugriff (PDF)

Protease Inhibitors as Antiviral Agents

Clinical Microbiology Reviews, 1998-10, Vol.11 (4), p.614-627

1998

Volltextzugriff (PDF)

In Vitro Resistance Study of Rupintrivir, a Novel Inhibitor of Human Rhinovirus 3C Protease

Antimicrobial Agents and Chemotherapy, 2007-12, Vol.51 (12), p.4366-4373

2007

Volltextzugriff (PDF)

In Vitro Antiviral Activity of AG7088, a Potent Inhibitor of Human Rhinovirus 3C Protease

Antimicrobial Agents and Chemotherapy, 1999-10, Vol.43 (10), p.2444-2450

1999

Volltextzugriff (PDF)

Structure-Assisted Design of Mechanism-Based Irreversible Inhibitors of Human Rhinovirus 3C Protease with Potent Antiviral Activity against Multiple Rhinovirus Serotypes

Proceedings of the National Academy of Sciences - PNAS, 1999-09, Vol.96 (20), p.11000-11007

1999

Volltextzugriff (PDF)

Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir

Antimicrobial Agents and Chemotherapy, 1998-10, Vol.42 (10), p.2637-2644

1998

Volltextzugriff (PDF)

Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease

Journal of medicinal chemistry, 1997-11, Vol.40 (24), p.3979-3985

1997

Volltextzugriff (PDF)

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

Antimicrobial Agents and Chemotherapy, 1996-02, Vol.40 (2), p.292-297

1996

Volltextzugriff (PDF)

Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities

Antimicrobial Agents and Chemotherapy, 2001-04, Vol.45 (4), p.1086-1093

2001

Volltextzugriff (PDF)

Correlation between Human Immunodeficiency Virus Genotypic Resistance and Virologic Response in Patients Receiving Nelfinavir Monotherapy or Nelfinavir with Lamivudine and Zidovudine

The Journal of infectious diseases, 2000-08, Vol.182 (2), p.420-427

2000

Volltextzugriff (PDF)

Inhibition of Human Rhinovirus-Induced Cytokine Production by AG7088, a Human Rhinovirus 3C Protease Inhibitor

Antimicrobial Agents and Chemotherapy, 2000-05, Vol.44 (5), p.1236-1241

2000

Volltextzugriff (PDF)

Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir

AIDS (London), 1999-02, Vol.13 (2), p.F23-F28

1999

Volltextzugriff (PDF)

Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro

Antimicrobial Agents and Chemotherapy, 1997-10, Vol.41 (10), p.2159-2164

1997

Volltextzugriff (PDF)

Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers

Antimicrobial Agents and Chemotherapy, 2003-12, Vol.47 (12), p.3907-3916

2003

Volltextzugriff (PDF)

Design, Synthesis, and Evaluation of Nonpeptidic Inhibitors of Human Rhinovirus 3C Protease

Journal of medicinal chemistry, 1996-12, Vol.39 (26), p.5072-5082

1996

Volltextzugriff (PDF)

Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy

The Journal of infectious diseases, 1994-11, Vol.170 (5), p.1157-1164

1994

Volltextzugriff (PDF)

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 1. Michael Acceptor Structure−Activity Studies

Journal of medicinal chemistry, 1998-07, Vol.41 (15), p.2806-2818

1998

Volltextzugriff (PDF)

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 3. Structure−Activity Studies of Ketomethylene-Containing Peptidomimetics

Journal of medicinal chemistry, 1999-04, Vol.42 (7), p.1203-1212

1999

Volltextzugriff (PDF)

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 2. Peptide Structure−Activity Studies

Journal of medicinal chemistry, 1998-07, Vol.41 (15), p.2819-2834

1998

Volltextzugriff (PDF)

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P1 Lactam Moieties as l-Glutamine Replacements

Journal of medicinal chemistry, 1999-04, Vol.42 (7), p.1213-1224

1999

Volltextzugriff (PDF)

Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor

Antimicrobial Agents and Chemotherapy, 1996-01, Vol.40 (1), p.133-138

1996

Volltextzugriff (PDF)

Rhinovirus chemotherapy

Antiviral research, 2006-09, Vol.71 (2), p.391-396

Patick, Amy K.

2006

Volltextzugriff (PDF)

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 6. Structure−Activity Studies of Orally Bioavailable, 2-Pyridone-Containing Peptidomimetics

Journal of medicinal chemistry, 2002-04, Vol.45 (8), p.1607-1623

2002

Volltextzugriff (PDF)

Treatment of HCV Infection by Targeting MicroRNA

The New England journal of medicine, 2013-05, Vol.368 (18), p.1685-1694

2013

Volltextzugriff (PDF)

Major histocompatibility complex-conferred resistance to Theiler's virus-induced demyelinating disease is inherited as a dominant trait in B10 congenic mice

Journal of Virology, 1990-11, Vol.64 (11), p.5570-5576

1990

Volltextzugriff (PDF)

1 – 25 von 104

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(97)

Publikationsform

Artikel
(104)

Sprache

Englisch
(104)

Erscheinungsjahr

n.n

Thema

Science & Technology
(70)
Life Sciences & Biomedicine
(67)
Biological And Medical Sciences
(56)
Humans
(52)
Medical Sciences
(48)
Antiviral Agents
(47)
Pharmacology & Pharmacy
(45)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(43)
Pharmacology. Drug Treatments
(43)
Antiviral Agents - Pharmacology
(34)
Microbiology
(31)
3c Viral Proteases
(23)
Virology
(22)
Animals
(21)
Cell Line
(20)
Hela Cells
(20)
Chemistry, Medicinal
(18)
Rhinovirus - Drug Effects
(18)
Viral Proteins
(18)
Rhinovirus - Enzymology
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Conservation of Amino Acids in Human Rhinovirus 3C Protease Correlates with Broad-Spectrum Antiviral Activity of Rupintrivir, a Novel Human Rhinovirus 3C Protease Inhibitor

Protease Inhibitors as Antiviral Agents

In Vitro Resistance Study of Rupintrivir, a Novel Inhibitor of Human Rhinovirus 3C Protease

In Vitro Antiviral Activity of AG7088, a Potent Inhibitor of Human Rhinovirus 3C Protease

Structure-Assisted Design of Mechanism-Based Irreversible Inhibitors of Human Rhinovirus 3C Protease with Potent Antiviral Activity against Multiple Rhinovirus Serotypes

Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir

Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities

Correlation between Human Immunodeficiency Virus Genotypic Resistance and Virologic Response in Patients Receiving Nelfinavir Monotherapy or Nelfinavir with Lamivudine and Zidovudine

Inhibition of Human Rhinovirus-Induced Cytokine Production by AG7088, a Human Rhinovirus 3C Protease Inhibitor

Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir

Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro

Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers

Design, Synthesis, and Evaluation of Nonpeptidic Inhibitors of Human Rhinovirus 3C Protease

Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 1. Michael Acceptor Structure−Activity Studies

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 3. Structure−Activity Studies of Ketomethylene-Containing Peptidomimetics

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 2. Peptide Structure−Activity Studies

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P1 Lactam Moieties as l-Glutamine Replacements

Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor

Rhinovirus chemotherapy

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 6. Structure−Activity Studies of Orally Bioavailable, 2-Pyridone-Containing Peptidomimetics

Treatment of HCV Infection by Targeting MicroRNA

Major histocompatibility complex-conferred resistance to Theiler's virus-induced demyelinating disease is inherited as a dominant trait in B10 congenic mice

Suchergebnisse filtern